(Q51372691)

4 April 2018

title

Research priorities for global measles and rubella control and eradication. (English)

1 reference

4 April 2018

1 reference

1 reference

1 reference

3

Paul A Rota

1 reference

4 April 2018

Kimberly M. Thompson

7

object named as

Kimberly M Thompson

1 reference

4 April 2018

Peter M Strebel

10

object named as

Peter M Strebel

1 reference

4 April 2018

William J. Moss

4

object named as

William J Moss

1 reference

4 April 2018

author name string

James L Goodson

1

1 reference

4 April 2018

Susan Y Chu

2

1 reference

4 April 2018

David A Featherstone

5

1 reference

4 April 2018

Maya Vijayaraghavan

6

1 reference

4 April 2018

Rebecca Martin

8

1 reference

4 April 2018

Susan Reef

9

1 reference

4 April 2018

language of work or name

English

0 references

publication date

28 April 2012

1 reference

4 April 2018

published in

Vaccine

1 reference

4 April 2018

volume

30

1 reference

4 April 2018

issue

32

1 reference

4 April 2018

page(s)

4709-4716

1 reference

4 April 2018

The Measles Initiative: moving toward measles eradication.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

7 January 2021

A world without measles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Proceedings of the Global Technical Consultation to assess the feasibility of measles eradication, 28-30 July 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

The heterogeneity of measles epidemiology in India: implications for improving control measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Measles in rural West Bengal, India, 2005-6: low recourse to the public sector limits the use of vitamin A and the sensitivity of surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Measles eradication in the Americas: progress to date

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Impact of measles outbreak response vaccination campaign in Dar es Salaam, Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Migration as a risk factor for measles after a mass vaccination campaign, Burkina Faso, 2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

The dynamics of measles in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Successes and failures in measles control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Low titers of measles antibody in mothers whose infants suffered from measles before eligible age for measles vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Changing epidemiology of measles in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Immunity to measles in pregnant mothers and in cord blood of their infants: impact of HIV status and mother's place of birth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Rural-urban gradient in seasonal forcing of measles transmission in Niger.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Devices for intradermal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Expansion of the global measles and rubella laboratory network 2005-09.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Guidelines for the documentation and verification of measles, rubella, and congenital rubella syndrome elimination in the region of the Americas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Global distribution of measles genotypes and measles molecular epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

An indirect immunocolorimetric assay to detect rubella virus infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Improving global virologic surveillance for measles and rubella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Vaccination and herd immunity to infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Comparing measles with previous eradication programs: enabling and constraining factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003-2009 and essential accelerated actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Economic evaluation of a Child Health Days strategy to deliver multiple maternal and child health interventions in Somalia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

First 5 years of measles elimination in southern Africa: 1996-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Public-health impact of accelerated measles control in the WHO African Region 2000-03.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Rapid scale-up of long-lasting insecticide-treated bed nets through integration into the national immunization program during child health week in Togo, 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Measles supplemental immunization activities improve measles vaccine coverage and equity: Evidence from Kenya, 2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Improved equity in measles vaccination from integrating insecticide-treated bednets in a vaccination campaign, Madagascar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Addressing the vaccine confidence gap.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Time is of the essence: exploring a measles outbreak response vaccination in Niamey, Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Impact of a measles outbreak response immunization campaign: Maroua, Cameroon, 2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Should outbreak response immunization be recommended for measles outbreaks in middle- and low-income countries? An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

The Global Burden of Measles in the Year 2000—A Model that Uses Country‐Specific Indicators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Measles surveillance: the importance of finding the tip of the iceberg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Completeness of measles case reporting: review of estimates for the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Health care-associated measles outbreak in the United States after an importation: challenges and economic impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

The cost of containing one case of measles: the economic impact on the public health infrastructure--Iowa, 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Progress toward control of rubella and prevention of congenital rubella syndrome--worldwide, 2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Rubella vaccines: WHO position paper--recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Measles and rubella elimination initiatives in the Americas: lessons learned and best practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Rubella epidemiology in Africa in the prevaccine era, 2002-2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Lessons learned from integrated surveillance of measles and rubella in the Caribbean

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Congenital rubella syndrome burden in Morocco: a rapid retrospective assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Developing rubella vaccination policy in Nepal--results from rubella surveillance and seroprevalence and congenital rubella syndrome studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Elimination of rubella and congenital rubella syndrome in the Americas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Status of global virologic surveillance for rubella viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

Global eradication of measles: an epidemiologic and economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.058

10.1016/J.VACCINE.2012.04.058

7 January 2021

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

22549089

1 reference

4 April 2018